Population 2018: 8.6 million

<table>
<thead>
<tr>
<th>Tuberculosis profile</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>37 (30–45)</td>
<td>432 (352–521)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>2.7 (2.2–3.3)</td>
<td>32 (26–38)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>2 (1.2–2.9)</td>
<td>23 (14–33)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>4.5 (3–6.2)</td>
<td>52 (35–72)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.25 (0.1–0.45)</td>
<td>2.8 (1.2–6.2)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**
- % tested with rapid diagnostics at time of diagnosis
  - % with known HIV status: 52%
  - % pulmonary: 56%
  - % bacteriologically confirmed: 30%
  - % children aged 0-14 years: 24%
  - % women: 36%
  - % men: 40%
- % with known HIV status who are HIV-positive: 1,124 (7%)
- % on antiretroviral therapy: 909 (81%)

**Drug-resistant TB care, 2018**
- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 433, XDR-TB: 8
  - New cases
  - Previously treated cases

**Laboratory-confirmed cases**
- MDR/RR-TB: 433, XDR-TB: 8
- MDR/RR-TB cases tested for resistance to second-line drugs: 252

**Treatment success rate and cohort size**
- New cases registered in 2017: 66% (2017)
- Previously treated cases registered in 2017: 66% (2017)
- MDR/RR-TB cases started on second-line treatment in 2016: 75% (2016)
- XDR-TB cases started on second-line treatment in 2016: 63% (2016)

**TB preventive treatment, 2018**
- % of HIV-positive people (newly enrolled in care) on preventive treatment: 21%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 27% (25–30)

**TB financing, 2019**
- National TB budget (US$ millions): 36
  - Funding source: 52% domestic, 25% international, 24% unfunded

---

*Ranges represent uncertainty intervals

MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

* Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-12-12
Data: www.who.int/tb/data